Dato-DXd showed a 43% reduction in disease progression risk and a 21% reduction in death risk compared to chemotherapy in TNBC patients ineligible for immunotherapy. The TROPION-Breast02 trial ...
Discover Delcath’s innovative liver-targeted chemotherapy system and latest clinical data driving potential market expansion.
The hospital director, brokers, and patients?totaling 120 individuals?have been apprehended by police on charges of ...
East Idaho News on MSN
Common questions about lung cancer
Lung cancer remains the leading cause of cancer-related death in the United States. The good news is that early detection ...
Uterine cancer symptoms include irregular bleeding and pelvic pain, but early diagnosis through medical evaluation can lead ...
Worcester Telegram on MSN
Opinion/Guest column: How 2 minutes can possibly save your life
In the past 10 years, these scans have saved 80,000 years of life – that's nearly 30 million more days spent with loved ones ...
Bladder cancer is one of the most common urological cancers, with nonmuscle invasive forms accounting for a significant portion of new diagnoses. In September, UC Davis Comprehens ...
About Creative Medical Technology Holdings Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) is a clinical-stage biotechnology company pioneering regenerative medicine solutions across ...
Results presented by AstraZeneca from its phase 3 trial of Imfinzi in patients with high-risk, non-muscle invasive bladder ...
Dr. Sophia Rizk, an oncologist with Southcoast Health, said knowing your family history is imperative because it may mean you ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback